Skip to content
Screener

NovoCure NVCR Q1 2025 earnings

Reported April 24, 2025 · Before market open

Revenue$155.0MBeat by $1.1M
EPS-$0.31Beat by $0.16
Revenue estimate$153.9M
EPS estimate-$0.47

Next report

Oct 29, 2026 (in a month)
Revenue estimate$182.3M
EPS estimate-$0.21

Financials

Q1 2025

Income statement

See full
Revenue$155.0M+11.9%
Gross profit$116.5M+11.1%
Operating income-$37.9M+8.8%
Net income-$34.3M+11.5%
EPS (diluted)-$0.31+13.9%

Balance sheet

See full
Cash & equivalents$127.3M-72.0%
Total debt$40.3M-93.2%
Total equity$362.0M+0.7%
Total assets$1.2B+11.4%

Cash flow

See full
Operating cash flow-$35.7M-13.0%
CapEx$10.6M-10.0%
Free cash flow-$46.3M-6.7%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$1.96B+16.8%
Enterprise value$1.87B+3.0%
P/S3.2×0.0×

Profitability

See full
Gross margin77.2%+2.3pp
Operating margin-26.8%-6.8pp
Net margin-26.4%-5.8pp
FCF margin-11.6%-3.8pp

Returns & leverage

See full
Return on equity-45.5%-2.8pp
Debt / equity0.1×-1.5×
Current ratio1.5×-4.8×

Segments

By geography

See full
United States$93.2M—
Germany$18.7M—
France$17.9M—
Japan$8.7M—
Greater China$4.6M—

FAQ

When did NovoCure report Q1 2025 earnings?
NovoCure (NVCR) reported Q1 2025 earnings on April 24, 2025 before market open.
What were NovoCure's Q1 2025 revenue and EPS?
NovoCure reported revenue of $155.0M and eps of $-0.31 for Q1 2025.
Did NovoCure beat estimates in Q1 2025?
Revenue beat the consensus estimate of $153.9M by $1.1M. EPS beat the consensus estimate of $-0.47 by $0.16.
How did NovoCure's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 11.9% from $138.5M a year earlier and eps grew 13.9% from $-0.36.
Where can I find NovoCure's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001645113-25-000007) and the 10-Q periodic report (0001645113-25-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.